Form 4: Vertex Pharmaceuticals Director Diana McKenzie Reports Stock Transactions
SEC Form 4 Filing
Director Diana McKenzie reports acquisition and disposition of Vertex Pharmaceuticals common stock and deferred stock units on May 1, 2025.
Summary
- On May 1, 2025, Diana McKenzie, a director at Vertex Pharmaceuticals, reported transactions involving the company's stock.
- She acquired 796 shares of common stock at $0, likely through a restricted stock unit award.
- McKenzie also disposed of 1,001 shares of common stock.
- This disposition was in exchange for 1,001 deferred stock units under the company's deferred compensation plan.
- Following these transactions, McKenzie directly owns 2,231 shares of common stock and indirectly owns 207 shares held in trust.
- She also holds 6,991.483 deferred stock units.
- The deferred stock units convert to common stock upon termination of board service, a change of control, disability, or death.
Sentiment
Score: 7
Explanation: The document is a routine regulatory filing detailing stock transactions by a company director. It doesn't inherently convey positive or negative sentiment, but the fact that the director is maintaining a significant stake in the company is mildly positive.
Future Outlook
The deferred stock units will be paid out in common stock upon the earliest occurrence of termination of board service, a change of control of the company, or Ms. McKenzie's disability or death.
Industry Context
Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. This filing indicates changes in Diana McKenzie's holdings of Vertex Pharmaceuticals stock and deferred stock units.
Stakeholder Impact
- The transactions may have a minor impact on shareholders by slightly altering the ownership structure.
- The deferred compensation plan impacts Ms. McKenzie's long-term compensation and alignment with the company's success.
Key Dates
| Date | Description |
|---|---|
| 05/01/2024 | Date of restricted stock units granted to Ms. McKenzie. |
| 05/01/2025 | Date of stock acquisition and disposition, and deferred stock unit acquisition. |
| 05/05/2025 | Date of signature on the Form 4 filing. |
Keywords
Form 4, Beneficial Ownership, Stock Transactions, Deferred Stock Units, Director, Vertex Pharmaceuticals, VRTX, Diana McKenzie
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.